Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (61-70 of 294) with videos related to

Pageof 30
Sort By:
BJU International|November 28, 2008
Bladder cancer todayCora N Sternberg, Seth P Lerner, John M Fitzpatrick
Bladder Cancer (Amsterdam, Netherlands)|December 19, 2018
Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex VirusKwan Joong Joo, Hongtao Li, Xiaoliu Zhang, et al.
Urologic Oncology|July 5, 2011
A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinomaJonathan M Levitt, Weiguo Jian, Seth P Lerner, et al.
Anticancer Research|July 2, 2014
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinomaWeiguo Jian, Jonathan M Levitt, Seth P Lerner, et al.
Anticancer Research|July 2, 2014
The preclinical activity of lenalidomide in indolent urothelial carcinomaWeiguo Jian, Jonathan M Levitt, Seth P Lerner, et al.
Cancer|December 6, 2002
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinomaRoberto Casella, Shahrokh F Shariat, Mara A Monoski, et al.
BJU International|February 23, 2012
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic reviewJa Hyeon Ku, Guilherme Godoy, Gilad E Amiel, et al.
Therapeutic Advances in Urology|July 27, 2011
Use of nomograms for predictions of outcome in patients with advanced bladder cancerShahrokh F Shariat, Pierre I Karakiewicz, Guilherme Godoy, et al.
Molecular Cancer Therapeutics|April 22, 2010
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signalingJonathan M Levitt, Hideyuki Yamashita, Weiguo Jian, et al.
European Urology|June 22, 2005
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladderShahrokh F Shariat, Kazumasa Matsumoto, Roberto Casella, et al.
Pageof 30

Showing results (61-70 of 294) with videos related to

Sort By:
Pageof 30
BJU International|November 28, 2008
Bladder cancer todayCora N Sternberg, Seth P Lerner, John M Fitzpatrick
Bladder Cancer (Amsterdam, Netherlands)|December 19, 2018
Therapeutic Effect on Bladder Cancer with a Conditionally Replicating Oncolytic Virus Derived from Type II Herpes Simplex VirusKwan Joong Joo, Hongtao Li, Xiaoliu Zhang, et al.
Urologic Oncology|July 5, 2011
A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinomaJonathan M Levitt, Weiguo Jian, Seth P Lerner, et al.
Anticancer Research|July 2, 2014
The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinomaWeiguo Jian, Jonathan M Levitt, Seth P Lerner, et al.
Anticancer Research|July 2, 2014
The preclinical activity of lenalidomide in indolent urothelial carcinomaWeiguo Jian, Jonathan M Levitt, Seth P Lerner, et al.
Cancer|December 6, 2002
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinomaRoberto Casella, Shahrokh F Shariat, Mara A Monoski, et al.
BJU International|February 23, 2012
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic reviewJa Hyeon Ku, Guilherme Godoy, Gilad E Amiel, et al.
Therapeutic Advances in Urology|July 27, 2011
Use of nomograms for predictions of outcome in patients with advanced bladder cancerShahrokh F Shariat, Pierre I Karakiewicz, Guilherme Godoy, et al.
Molecular Cancer Therapeutics|April 22, 2010
Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signalingJonathan M Levitt, Hideyuki Yamashita, Weiguo Jian, et al.
European Urology|June 22, 2005
Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladderShahrokh F Shariat, Kazumasa Matsumoto, Roberto Casella, et al.
Pageof 30